Obesity Featured Articles

31. Navigating Autoimmune Disease A Playbook For Cell And Gene Therapies 9/3/2025

    By integrating site readiness, patient engagement, and data-driven decision-making, the cell and gene therapies (CAGT) field is advancing toward therapies that not only control disease but transform lives.

32. Five Questions Biotechs Should Ask Before Selecting A Bioanalytical CRO 9/2/2025

    In a landscape where speed, quality, and trust are inseparable, choosing a CRO that shares your ambition is not optional—it is essential to survival and success.

33. Accelerating IND-Enabling Studies With Automated Bioanalysis Workflows 9/2/2025

    Reimagined as automation-first, bioanalysis shifts from being an Investigational New Drug (IND) bottleneck to a catalyst for innovation—helping companies move therapies forward with greater confidence.

34. Why Bioanalysis Needs To Break Free From Manual Bottlenecks 9/2/2025

    Bioanalysis remains one of the most persistent bottlenecks in drug development, with CRO's displaying inefficiencies that are no longer operational nuisances but strategic liabilities.

35. How Digital Twins Are Rewriting Clinical Trials 9/2/2025

    While the benefits of digital twins to accelerate clinical trials are undeniable, many questions about their use are still unanswered and go far beyond technology.

36. Strategic CMC Considerations For Pre-IND Meetings: Setting The Stage For A Successful TPP 9/1/2025

    In biotechnology, the Pre-Investigational New Drug (Pre-IND) stage is a critical juncture. Explore the pivotal role of Chemistry, Manufacturing, and Controls (CMC) in navigating this phase.

37. The Resurgence Of Antibody-Drug Conjugates 9/1/2025

    As advancements in ADC technology and clinical trial methodologies progress, Antibody-Drug Conjugates (ADCs) are poised to become pivotal in precision oncology.

38. Advancing Ovarian Cancer Therapies: Clinical Research Trends, Challenges, And Proven Strategies 8/29/2025

    Ovarian cancer remains one of the deadliest gynecologic malignancies. Successful clinical trials in this space demand deep therapeutic expertise, operational agility, and global coordination.

39. Optimizing Global Early-Phase Oncology Trials 8/29/2025

    By integrating strong partnerships, local expertise, and predictive analytics, sponsors and CROs can identify and activate the most suitable sites, accelerating trial delivery.

40. 3 Quick Takes From A PI With 100+ Trials To His Name 8/29/2025

    Principal investigator Norman B. Gaylis, MD, shares his perspective on patient recruitment, protocol design, and vendor selection.